Synergistic therapy of glucagon-like peptide-1 (GLP-1) and glucagon receptors can upregulate the expression of FGF21 and abate renal insufficiency induced by diabetes (Patel et al., 2018). The gene discussed is FGF21; the disease is diabetes mellitus.